ACC is a critical enzyme that controls the synthesis and burning of
fat. Inhibition of ACC with small molecule agents could effectively
mimic exercise thereby creating new options to treat diabetes, NASH /
fatty liver disease, obesity and complications of metabolic syndrome.
In addition, recent studies have shown that ACC function is required for
tumorigenesis, notably in lung, breast and prostate cancer.
ACC has been very hard to drug effectively. However, by targeting a unique allosteric site, the Nimbus approach has led to first-in-class inhibitors with substantially improved potency, higher selectivity and more attractive drug-like properties versus traditional chemistries.